EP1147204A1
(fr)
*
|
1999-01-28 |
2001-10-24 |
Medical College Of Georgia Research Institute, Inc. |
Composition et methode destinees a l'attenuation in vivo et in vitro de l'expression genique utilisant de l'arn double brin
|
DE19956568A1
(de)
*
|
1999-01-30 |
2000-08-17 |
Roland Kreutzer |
Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
|
US8541548B2
(en)
*
|
1999-06-07 |
2013-09-24 |
Arrowhead Madison Inc. |
Compounds and methods for reversible modification of biologically active molecules
|
US20080281041A1
(en)
*
|
1999-06-07 |
2008-11-13 |
Rozema David B |
Reversibly Masked Polymers
|
GB9925459D0
(en)
*
|
1999-10-27 |
1999-12-29 |
Plant Bioscience Ltd |
Gene silencing
|
US7829693B2
(en)
*
|
1999-11-24 |
2010-11-09 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of a target gene
|
DE10100586C1
(de)
*
|
2001-01-09 |
2002-04-11 |
Ribopharma Ag |
Verfahren zur Hemmung der Expression eines Ziegens
|
EP1311269B1
(fr)
|
2000-08-04 |
2012-02-29 |
DMI Biosciences, Inc. |
Methode d'utilisation de dicetopiperazines et composition contenant ces substances
|
US8546143B2
(en)
|
2001-01-09 |
2013-10-01 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of a target gene
|
US7423142B2
(en)
*
|
2001-01-09 |
2008-09-09 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of anti-apoptotic genes
|
US7767802B2
(en)
*
|
2001-01-09 |
2010-08-03 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of anti-apoptotic genes
|
US20050164966A1
(en)
*
|
2001-05-18 |
2005-07-28 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of type 1 insulin-like growth factor receptor gene expression using short interfering nucleic acid (siNA)
|
US20050153915A1
(en)
*
|
2001-05-18 |
2005-07-14 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of early growth response gene expression using short interfering nucleic acid (siNA)
|
DE10163098B4
(de)
|
2001-10-12 |
2005-06-02 |
Alnylam Europe Ag |
Verfahren zur Hemmung der Replikation von Viren
|
US7745418B2
(en)
|
2001-10-12 |
2010-06-29 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting viral replication
|
DE10230997A1
(de)
*
|
2001-10-26 |
2003-07-17 |
Ribopharma Ag |
Medikament zur Erhöhung der Wirksamkeit eines Rezeptor-vermittelt Apoptose in Tumorzellen auslösenden Arzneimittels
|
US20040121348A1
(en)
*
|
2001-10-26 |
2004-06-24 |
Ribopharma Ag |
Compositions and methods for treating pancreatic cancer
|
US20040063654A1
(en)
*
|
2001-11-02 |
2004-04-01 |
Davis Mark E. |
Methods and compositions for therapeutic use of RNA interference
|
DE10202419A1
(de)
|
2002-01-22 |
2003-08-07 |
Ribopharma Ag |
Verfahren zur Hemmung der Expression eines durch eine Chromosomen-Aberration entstandenen Zielgens
|
US20050096289A1
(en)
*
|
2002-02-07 |
2005-05-05 |
Hans Prydz |
Methods and compositions for modulating tissue factor
|
IL163547A0
(en)
*
|
2002-02-12 |
2005-12-18 |
Quark Biotech Inc |
Use of the axl receptor for diagnosis and treatment of renal disease
|
EP1476492A1
(fr)
*
|
2002-02-22 |
2004-11-17 |
Insert Therapeutics Inc. |
Polymeres a base d'hydrates de carbone modifies, compositions de polymeres a base d'hydrates de carbone modifies, et leurs applications
|
US8008355B2
(en)
*
|
2002-03-11 |
2011-08-30 |
Roche Madison Inc. |
Endosomolytic poly(vinyl ether) polymers
|
US8138383B2
(en)
*
|
2002-03-11 |
2012-03-20 |
Arrowhead Madison Inc. |
Membrane active heteropolymers
|
EP1534340B1
(fr)
|
2002-09-06 |
2011-11-16 |
Cerulean Pharma Inc. |
Polymeres a base de cyclodextrine pour l'administration de medicaments lies par liaison covalente
|
US9719092B2
(en)
|
2002-11-14 |
2017-08-01 |
Thermo Fisher Scientific Inc. |
RNAi targeting CNTD2
|
US9719094B2
(en)
|
2002-11-14 |
2017-08-01 |
Thermo Fisher Scientific Inc. |
RNAi targeting SEC61G
|
US7977471B2
(en)
*
|
2002-11-14 |
2011-07-12 |
Dharmacon, Inc. |
siRNA targeting TNFα
|
US7691998B2
(en)
*
|
2002-11-14 |
2010-04-06 |
Dharmacon, Inc. |
siRNA targeting nucleoporin 62kDa (Nup62)
|
US7635770B2
(en)
*
|
2002-11-14 |
2009-12-22 |
Dharmacon, Inc. |
siRNA targeting protein kinase N-3 (PKN-3)
|
US7951935B2
(en)
|
2002-11-14 |
2011-05-31 |
Dharmacon, Inc. |
siRNA targeting v-myc myelocytomatosis viral oncogene homolog (MYC)
|
US7619081B2
(en)
*
|
2002-11-14 |
2009-11-17 |
Dharmacon, Inc. |
siRNA targeting coatomer protein complex, subunit beta 2 (COPB2)
|
US9879266B2
(en)
|
2002-11-14 |
2018-01-30 |
Thermo Fisher Scientific Inc. |
Methods and compositions for selecting siRNA of improved functionality
|
US7592442B2
(en)
*
|
2002-11-14 |
2009-09-22 |
Dharmacon, Inc. |
siRNA targeting ribonucleotide reductase M2 polypeptide (RRM2 or RNR-R2)
|
US10011836B2
(en)
|
2002-11-14 |
2018-07-03 |
Thermo Fisher Scientific Inc. |
Methods and compositions for selecting siRNA of improved functionality
|
US20090227780A1
(en)
*
|
2002-11-14 |
2009-09-10 |
Dharmacon, Inc. |
siRNA targeting connexin 43
|
US7612196B2
(en)
|
2002-11-14 |
2009-11-03 |
Dharmacon, Inc. |
siRNA targeting cyclin-dependent kinase inhibitor 1B (p27, Kip1) (CDKN1B)
|
US9771586B2
(en)
|
2002-11-14 |
2017-09-26 |
Thermo Fisher Scientific Inc. |
RNAi targeting ZNF205
|
WO2006006948A2
(fr)
|
2002-11-14 |
2006-01-19 |
Dharmacon, Inc. |
Methodes et compositions permettant de selectionner des arnsi presentant une fonctionnalite amelioree
|
US7781575B2
(en)
|
2002-11-14 |
2010-08-24 |
Dharmacon, Inc. |
siRNA targeting tumor protein 53 (p53)
|
US9839649B2
(en)
|
2002-11-14 |
2017-12-12 |
Thermo Fisher Scientific Inc. |
Methods and compositions for selecting siRNA of improved functionality
|
US20100113307A1
(en)
*
|
2002-11-14 |
2010-05-06 |
Dharmacon, Inc. |
siRNA targeting vascular endothelial growth factor (VEGF)
|
US20080268457A1
(en)
*
|
2002-11-14 |
2008-10-30 |
Dharmacon, Inc. |
siRNA targeting forkhead box P3 (FOXP3)
|
US8090542B2
(en)
*
|
2002-11-14 |
2012-01-03 |
Dharmacon Inc. |
Functional and hyperfunctional siRNA
|
US9228186B2
(en)
|
2002-11-14 |
2016-01-05 |
Thermo Fisher Scientific Inc. |
Methods and compositions for selecting siRNA of improved functionality
|
US8198427B1
(en)
|
2002-11-14 |
2012-06-12 |
Dharmacon, Inc. |
SiRNA targeting catenin, beta-1 (CTNNB1)
|
AU2004241101B2
(en)
|
2003-05-15 |
2010-05-13 |
Ampio Pharmaceuticals, Inc. |
Treatment of T-cell mediated diseases
|
WO2005017109A2
(fr)
*
|
2003-06-30 |
2005-02-24 |
Massachusetts Institute Of Technology |
Acides nucleiques et polypeptides necessaires a la survie des cellules en l'absence de rb
|
US20050136437A1
(en)
*
|
2003-08-25 |
2005-06-23 |
Nastech Pharmaceutical Company Inc. |
Nanoparticles for delivery of nucleic acids and stable double-stranded RNA
|
WO2005045032A2
(fr)
*
|
2003-10-20 |
2005-05-19 |
Sima Therapeutics, Inc. |
Inhibition mediee par une interference arn de l'expression du gene de reponse de croissance precoce, au moyen d'un petit acide nucleique interferant (sina)
|
WO2005051431A1
(fr)
*
|
2003-11-25 |
2005-06-09 |
The University Of York |
Systeme d'administration colloidal pour agents therapeutiques biologiques
|
WO2005062854A2
(fr)
*
|
2003-12-19 |
2005-07-14 |
University Of Cincinnati |
Polyamides pour administration d'acides nucleiques
|
CA2551100A1
(fr)
*
|
2003-12-23 |
2005-07-14 |
The Trustees Of The University Of Pennsylvania |
Compositions et procedes pour la therapie combinee de maladie
|
WO2005080410A1
(fr)
*
|
2004-02-20 |
2005-09-01 |
Genesis Research And Development Corporation Limited |
Diffusion ciblee de molecule d'interference arn pour le traitement de troubles facilites par ige
|
JP2007527240A
(ja)
*
|
2004-03-01 |
2007-09-27 |
マサチューセッツ インスティテュート オブ テクノロジー |
アレルギー性鼻炎および喘息のためのRNAiベースの治療
|
US20050202075A1
(en)
*
|
2004-03-12 |
2005-09-15 |
Pardridge William M. |
Delivery of genes encoding short hairpin RNA using receptor-specific nanocontainers
|
JP2005264046A
(ja)
*
|
2004-03-19 |
2005-09-29 |
Sony Corp |
刺激応答性ハイドロゲル、刺激応答性ハイドロゲルの製造方法、及び刺激応答性ハイドロゲルを用いた高分子アクチュエータ
|
AU2005230684B2
(en)
*
|
2004-04-05 |
2011-10-06 |
Alnylam Pharmaceuticals, Inc. |
Process and reagents for oligonucleotide synthesis and purification
|
US20110206639A1
(en)
*
|
2004-04-15 |
2011-08-25 |
Christie Vermeulen |
Replication competent viruses capable of silencing virus inhibitory factor expression
|
US20050260652A1
(en)
*
|
2004-04-15 |
2005-11-24 |
The General Hospital Corporation |
Compositions and methods that modulate RNA interference
|
EP1586654A1
(fr)
*
|
2004-04-15 |
2005-10-19 |
Vereniging voor christelijk hoger onderwijs, wetenschappelijk onderzoek en patiëntenzorg |
Virus competent de réplication capable de mettre au silence l'expression de facteur inhibiteur viral
|
JP4584986B2
(ja)
*
|
2004-04-27 |
2010-11-24 |
アルニラム ファーマスーティカルズ インコーポレイテッド |
2−アリールプロピル部分を含む1本鎖及び2本鎖オリゴヌクレオチド
|
JP4584987B2
(ja)
*
|
2004-04-30 |
2010-11-24 |
アルニラム ファーマスーティカルズ インコーポレイテッド |
C5修飾ピリミジンを含むオリゴヌクレオチド
|
US7605250B2
(en)
*
|
2004-05-12 |
2009-10-20 |
Dharmacon, Inc. |
siRNA targeting cAMP-specific phosphodiesterase 4D
|
US20050265927A1
(en)
*
|
2004-05-17 |
2005-12-01 |
Yale University |
Intranasal delivery of nucleic acid molecules
|
BRPI0511272A
(pt)
*
|
2004-05-17 |
2007-12-04 |
Combinatorx Inc |
métodos e reagentes para o tratamento de distúrbios imunoinflamatórios
|
EP2290070B1
(fr)
|
2004-05-28 |
2015-03-25 |
Asuragen, Inc. |
Procédés et compositions impliquant du microARN
|
US8815599B2
(en)
*
|
2004-06-01 |
2014-08-26 |
Pronai Therapeutics, Inc. |
Methods and compositions for the inhibition of gene expression
|
US20060040290A1
(en)
*
|
2004-06-23 |
2006-02-23 |
Applera Corporation |
Methods, compositions, and kits comprising PNA for RNA interference
|
WO2006088490A2
(fr)
*
|
2004-06-30 |
2006-08-24 |
Alnylam Pharmaceuticals, Inc. |
Oligonucleotides comprenant une liaison de squelette non-phosphate
|
US8361976B2
(en)
*
|
2004-07-09 |
2013-01-29 |
University Of Massachusetts |
Therapeutic alteration of transplantable tissues through in situ or ex vivo exposure to RNA interference molecules
|
WO2006085987A2
(fr)
*
|
2004-07-09 |
2006-08-17 |
University Of Iowa Research Foundation |
Arn interference dans des cellules epitheliales respiratoires
|
US20060030538A1
(en)
*
|
2004-07-21 |
2006-02-09 |
Medtronic, Inc. |
Methods for reducing or preventing localized fibrosis using SiRNA
|
CA2574088C
(fr)
|
2004-07-21 |
2013-09-17 |
Alnylam Pharmaceuticals, Inc. |
Oligonucleotides comprenant une nucleobase modifiee ou non naturelle
|
US20060063208A1
(en)
*
|
2004-08-02 |
2006-03-23 |
Woolf Clifford J |
DRG11-responsive (DRAGON) gene and uses thereof
|
US7632932B2
(en)
|
2004-08-04 |
2009-12-15 |
Alnylam Pharmaceuticals, Inc. |
Oligonucleotides comprising a ligand tethered to a modified or non-natural nucleobase
|
EP1799825B1
(fr)
*
|
2004-10-05 |
2011-06-29 |
The California Institute of Technology |
Acides nucleiques a regulation d'aptameres et leurs utilisations
|
WO2006062581A2
(fr)
*
|
2004-10-15 |
2006-06-15 |
Benitec, Inc. |
Agent therapeutique d'interference arn pour le traitement de la restenose
|
AU2005299672A1
(en)
*
|
2004-10-22 |
2006-05-04 |
Benitec, Inc. |
Therapeutic RNAi agents for treating psoriasis
|
EP2322616A1
(fr)
|
2004-11-12 |
2011-05-18 |
Asuragen, Inc. |
Procédés et compositions impliquant l'ARNmi et des molécules inhibitrices de l'ARNmi
|
DE102005003788A1
(de)
*
|
2005-01-19 |
2006-07-20 |
Eberhard-Karls-Universität Tübingen Universitätsklinikum |
siRNA-Moleküle zur Behandlung von Blutgefäßen
|
WO2006078217A1
(fr)
*
|
2005-01-24 |
2006-07-27 |
Avaris Ab |
Complexe contenant un arnsi, un arnsh ou une molecule reticences et une entite fonctionnelle en vue d'une meilleure specificite et administration
|
WO2006080118A1
(fr)
*
|
2005-01-28 |
2006-08-03 |
Kyowa Hakko Kogyo Co., Ltd. |
Composition inhibant l'expression d'un gene cible
|
WO2006086681A2
(fr)
*
|
2005-02-09 |
2006-08-17 |
Beth Israel Deaconess Medical Center, Inc. |
Methodes d'inhibition de la migration et de la proliferation des cellules musculaires lisses
|
EP3153525A1
(fr)
|
2005-03-23 |
2017-04-12 |
Genmab A/S |
Anticorps dirigés contre cd38 pour le traitement du myélome multiple
|
JP4131271B2
(ja)
*
|
2005-03-30 |
2008-08-13 |
ソニー株式会社 |
情報処理装置および方法、並びにプログラム
|
US20070033062A1
(en)
*
|
2005-04-28 |
2007-02-08 |
Oligoengine, Inc. |
Business methods, systems, and computer programs for designing customized biological assays and producing related catalogs and kits
|
JP2008201673A
(ja)
*
|
2005-05-16 |
2008-09-04 |
Kyushu Univ |
Rna含有組成物
|
US20090047319A1
(en)
*
|
2005-05-25 |
2009-02-19 |
Kenji Kadomatsu |
Pharmaceutical composition for obstructive vascular disease
|
US8389708B2
(en)
|
2005-06-15 |
2013-03-05 |
Weiping Min |
Method of cancer treatment using siRNA silencing
|
WO2007043049A1
(fr)
*
|
2005-10-11 |
2007-04-19 |
Ben-Gurion University Of The Negev Research And Development Authority |
Compositions permettant d'effectuer un silençage de l'expression de vdac1 et des utilisations de celles-ci
|
TW200800235A
(en)
|
2005-10-18 |
2008-01-01 |
Otsuka Pharma Co Ltd |
Carrier composition for nucleic acid transport
|
EP1948674A4
(fr)
|
2005-11-02 |
2009-02-04 |
Protiva Biotherapeutics Inc |
Molecules d'arnsi modifiees et utilisations de celles-ci
|
CA2631677C
(fr)
*
|
2005-12-01 |
2014-08-12 |
Pronai Therapeutics, Inc. |
Formulation de liposomes amphoteres
|
WO2007067733A2
(fr)
*
|
2005-12-09 |
2007-06-14 |
Massachusetts Institute Of Technology |
Compositions et procédés pour suivre l'absorption d'arn par des cellules
|
CA2633063A1
(fr)
*
|
2005-12-16 |
2007-06-21 |
Diatos |
Conjugues peptidiques de penetration cellulaire pour la delivrance d'acides nucleiques dans une cellule
|
US20070172430A1
(en)
*
|
2006-01-20 |
2007-07-26 |
Nastech Pharmaceutical Company Inc. |
Dry powder compositions for rna influenza therapeutics
|
US8323967B2
(en)
*
|
2006-04-05 |
2012-12-04 |
Joslin Diabetes Center, Inc. |
Enhancing stem cell mobilization
|
US20070276134A1
(en)
*
|
2006-05-24 |
2007-11-29 |
Nastech Pharmaceutical Company Inc. |
Compositions and methods for complexes of nucleic acids and organic cations
|
US8501478B2
(en)
*
|
2006-06-15 |
2013-08-06 |
University Of Cincinnati |
Trehalose click polymers for delivery of biologically active molecules
|
US8017109B2
(en)
*
|
2006-08-18 |
2011-09-13 |
Roche Madison Inc. |
Endosomolytic poly(acrylate) polymers
|
WO2008022309A2
(fr)
*
|
2006-08-18 |
2008-02-21 |
F. Hoffmann-La Roche Ag |
Polyconjugués pour l'administration in vivo de polynucléotides
|
JP2010504350A
(ja)
*
|
2006-09-19 |
2010-02-12 |
アシュラジェン インコーポレイテッド |
治療的介入の標的としての、miR−200によって調節される遺伝子および経路
|
WO2008058291A2
(fr)
|
2006-11-09 |
2008-05-15 |
California Institute Of Technology |
Ribosymes modulaires régulés par les aptamères
|
WO2008073856A2
(fr)
*
|
2006-12-08 |
2008-06-19 |
Massachusetts Institute Of Technology |
Administration de nanoparticules et/ou d'agents à des cellules
|
JP2010516625A
(ja)
|
2007-01-24 |
2010-05-20 |
インサート セラピューティクス, インコーポレイテッド |
制御された薬物送達のためのテザー基を有するポリマー−薬物コンジュゲート
|
CA2680600A1
(fr)
|
2007-03-12 |
2008-09-18 |
Antigen Express, Inc. |
Elimination de la proteine li impliquee dans des constructions li-arni en immunotherapie anticancereuse
|
US8133553B2
(en)
|
2007-06-18 |
2012-03-13 |
Zimmer, Inc. |
Process for forming a ceramic layer
|
US8309521B2
(en)
|
2007-06-19 |
2012-11-13 |
Zimmer, Inc. |
Spacer with a coating thereon for use with an implant device
|
GB0711952D0
(en)
*
|
2007-06-20 |
2007-08-01 |
King S College London |
Microspheres
|
WO2009011855A2
(fr)
*
|
2007-07-16 |
2009-01-22 |
California Institute Of Technology |
Sélection de domaines de capteur à base d'acide nucléique dans une plate-forme d'échange d'acide nucléique
|
US20120165387A1
(en)
|
2007-08-28 |
2012-06-28 |
Smolke Christina D |
General composition framework for ligand-controlled RNA regulatory systems
|
US8367815B2
(en)
*
|
2007-08-28 |
2013-02-05 |
California Institute Of Technology |
Modular polynucleotides for ligand-controlled regulatory systems
|
US8865667B2
(en)
|
2007-09-12 |
2014-10-21 |
California Institute Of Technology |
Higher-order cellular information processing devices
|
US8361714B2
(en)
|
2007-09-14 |
2013-01-29 |
Asuragen, Inc. |
Micrornas differentially expressed in cervical cancer and uses thereof
|
US8608049B2
(en)
|
2007-10-10 |
2013-12-17 |
Zimmer, Inc. |
Method for bonding a tantalum structure to a cobalt-alloy substrate
|
UA97559C2
(uk)
*
|
2007-11-08 |
2012-02-27 |
Оцука Фармасьютікал Ко., Лтд. |
Комплекс нуклеїнової кислоти і композиція для доставки нуклеїнової кислоти
|
WO2009070805A2
(fr)
|
2007-12-01 |
2009-06-04 |
Asuragen, Inc. |
Gènes régulés par le mir-124 et cheminements servant de cibles pour une intervention thérapeutique
|
US9029524B2
(en)
*
|
2007-12-10 |
2015-05-12 |
California Institute Of Technology |
Signal activated RNA interference
|
FR2925491B1
(fr)
*
|
2007-12-19 |
2010-09-03 |
Oz Biosciences Sas |
Nouvelle classe de lipides cationiques pour le transport d'agents actifs dans les cellules
|
WO2009082817A1
(fr)
|
2007-12-27 |
2009-07-09 |
Protiva Biotherapeutics, Inc. |
Silençage de l'expression de la polo-like kinase à l'aide d'un arn interférent
|
CN104975020B
(zh)
|
2008-02-11 |
2020-01-17 |
菲奥医药公司 |
经修饰的RNAi多核苷酸及其用途
|
FR2928373B1
(fr)
|
2008-03-05 |
2010-12-31 |
Centre Nat Rech Scient |
Polymere derive de la polyethylenimine lineaire pour le transfert de gene.
|
US20090226531A1
(en)
*
|
2008-03-07 |
2009-09-10 |
Allergan, Inc. |
Methods and composition for intraocular delivery of therapeutic sirna
|
JP2011516094A
(ja)
|
2008-04-15 |
2011-05-26 |
プロチバ バイオセラピューティクス インコーポレイティッド |
干渉rnaを用いたcsn5遺伝子発現のサイレンシング方法
|
EP2990487A1
(fr)
|
2008-05-08 |
2016-03-02 |
Asuragen, INC. |
Compositions et procédés relatifs à la modulation de miarn de néovascularisation ou angiogenèse
|
JP5856843B2
(ja)
|
2008-05-27 |
2016-02-10 |
アンピオ ファーマシューティカルズ,インコーポレイテッド |
ジケトピペラジンを用いた医薬組成物
|
US8815818B2
(en)
|
2008-07-18 |
2014-08-26 |
Rxi Pharmaceuticals Corporation |
Phagocytic cell delivery of RNAI
|
CN108165548B
(zh)
|
2008-09-22 |
2022-10-14 |
菲奥医药公司 |
减小大小的自递送RNAi化合物
|
CN104857526B
(zh)
|
2008-10-22 |
2019-03-05 |
夸克制药公司 |
治疗眼部疾病的方法
|
US9074211B2
(en)
|
2008-11-19 |
2015-07-07 |
Rxi Pharmaceuticals Corporation |
Inhibition of MAP4K4 through RNAI
|
WO2010078536A1
(fr)
|
2009-01-05 |
2010-07-08 |
Rxi Pharmaceuticals Corporation |
Inhibition de pcsk9 par arni
|
WO2010090762A1
(fr)
|
2009-02-04 |
2010-08-12 |
Rxi Pharmaceuticals Corporation |
Duplexes d'arn avec régions de nucléotide phosphorothioate à brin unique pour fonctionnalité supplémentaire
|
US8329882B2
(en)
|
2009-02-18 |
2012-12-11 |
California Institute Of Technology |
Genetic control of mammalian cells with synthetic RNA regulatory systems
|
EP2405001B1
(fr)
*
|
2009-03-04 |
2015-07-08 |
Hirofumi Takeuchi |
Complexe d'acide nucléique et composition délivrant des acides nucléiques
|
US9145555B2
(en)
|
2009-04-02 |
2015-09-29 |
California Institute Of Technology |
Integrated—ligand-responsive microRNAs
|
WO2011006011A2
(fr)
*
|
2009-07-08 |
2011-01-13 |
Virginia Tech Intellectual Properties Inc. |
Balises polycationiques théranostiques comprenant des motifs répétés d'oligoéthylèneamine et des chélates de lanthanides
|
CN101624596B
(zh)
*
|
2009-08-12 |
2011-01-26 |
广州金琪基因技术研究发展中心 |
一种靶向c-myc癌基因的外指引序列
|
EP2477641B1
(fr)
|
2009-09-16 |
2024-03-27 |
Duke University |
Inhibition de l'activation des récepteurs du type toll endosomaux pour le traitement de troubles thrombotiques
|
US9799416B2
(en)
*
|
2009-11-06 |
2017-10-24 |
Terrapower, Llc |
Methods and systems for migrating fuel assemblies in a nuclear fission reactor
|
EA024534B1
(ru)
*
|
2010-02-24 |
2016-09-30 |
Эрроухэд Рисерч Корпорейшн |
КОНЪЮГИРОВАННАЯ СИСТЕМА ДОСТАВКИ И КОМПОЗИЦИЯ ДЛЯ НАПРАВЛЕННОЙ ДОСТАВКИ МАЛЫХ ИНТЕРФЕРИРУЮЩИХ РНК (миРНК) И СПОСОБ ПОЛУЧЕНИЯ КОМПОЗИЦИИ
|
WO2011119871A1
(fr)
|
2010-03-24 |
2011-09-29 |
Rxi Phrmaceuticals Corporation |
Arn interférant dans des indications oculaires
|
CN110042099A
(zh)
|
2010-03-24 |
2019-07-23 |
菲奥医药公司 |
皮肤与纤维化症候中的rna干扰
|
US9080171B2
(en)
|
2010-03-24 |
2015-07-14 |
RXi Parmaceuticals Corporation |
Reduced size self-delivering RNAi compounds
|
CA2802994A1
(fr)
|
2010-06-17 |
2011-12-22 |
The United States Of America As Represented By The Secretary, National I Nstitutes Of Health |
Compositions et procedes pour traiter des affections inflammatoires
|
CA2810844C
(fr)
|
2010-09-07 |
2017-03-21 |
Dmi Acquisition Corp. |
Compositions de diketopiperazine destinees au traitement de syndrome metabolique et de troubles associes
|
EP2718269B1
(fr)
|
2011-06-08 |
2018-01-31 |
Translate Bio, Inc. |
Lipides clivables
|
US9644241B2
(en)
|
2011-09-13 |
2017-05-09 |
Interpace Diagnostics, Llc |
Methods and compositions involving miR-135B for distinguishing pancreatic cancer from benign pancreatic disease
|
MX2014003856A
(es)
|
2011-10-10 |
2015-01-16 |
Ampio Pharmaceuticals Inc |
Dispositivos medicos implantables con tolerancia inmune incrementada y metodos para hacerlos e implantarlos.
|
WO2013055734A1
(fr)
|
2011-10-10 |
2013-04-18 |
Ampio Pharmaceuticals, Inc. |
Traitement de maladie dégénérative articulaire
|
AU2012328605B9
(en)
|
2011-10-28 |
2017-08-03 |
Ampio Pharmaceuticals, Inc. |
Treatment of rhinitis
|
JP2014533953A
(ja)
|
2011-11-17 |
2014-12-18 |
ザ ユナイテッド ステイツ オブ アメリカ, アズ リプレゼンテッド バイ ザ セクレタリー, デパートメント オブ ヘルス アンド ヒューマン サービシーズ |
治療用rnaスイッチ組成物及び使用方法
|
US9035039B2
(en)
|
2011-12-22 |
2015-05-19 |
Protiva Biotherapeutics, Inc. |
Compositions and methods for silencing SMAD4
|
KR102202004B1
(ko)
*
|
2012-01-04 |
2021-01-12 |
쿠아크 파마수티칼스 인코퍼레이티드 |
Casp2에 대한 이중-가닥 rna 화합물 및 그 용도
|
IN2014DN07023A
(fr)
|
2012-02-21 |
2015-04-10 |
Inst Nat Sante Rech Med |
|
IN2014DN07022A
(fr)
|
2012-02-21 |
2015-04-10 |
Inst Nat Sante Rech Med |
|
DK2858677T3
(da)
*
|
2012-06-08 |
2020-08-31 |
Ethris Gmbh |
Pulmonær levering af messenger rna
|
US10000545B2
(en)
|
2012-07-27 |
2018-06-19 |
Institut National De La Sante Et De La Recherche Medicale |
CD147 as receptor for pilus-mediated adhesion of Meningococci to vascular endothelia
|
WO2014055493A1
(fr)
|
2012-10-02 |
2014-04-10 |
Cerulean Pharma Inc. |
Procédés et systèmes s'appliquant à la précipitation de polymères et à la génération de particules
|
KR102170266B1
(ko)
*
|
2013-02-27 |
2020-10-27 |
한국과학기술원 |
다당류 고분자-siRNA 그라프트 접합체, 이를 포함하는 siRNA 전달체 및 이의 제조방법
|
WO2014160211A1
(fr)
*
|
2013-03-13 |
2014-10-02 |
Isis Pharmaceuticals, Inc. |
Modulation des réponses inflammatoires par une protéine c-réactive
|
NZ712630A
(en)
|
2013-03-15 |
2021-07-30 |
Ampio Pharmaceuticals Inc |
Compositions for the mobilization, homing, expansion and differentiation of stem cells and methods of using the same
|
EP3079707A4
(fr)
|
2013-12-02 |
2017-10-18 |
RXi Pharmaceuticals Corporation |
Immunothérapie du cancer
|
WO2015085113A1
(fr)
|
2013-12-04 |
2015-06-11 |
Rxi Pharmaceuticals Corporation |
Méthodes de traitement de cicatrisation à l'aide d'oligonucléotides chimiquement modifiés
|
WO2015142713A1
(fr)
*
|
2014-03-17 |
2015-09-24 |
Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College |
Compositions et procédés de réduction de l'activité de la protéine homologue c/ebp dans des cellules suppressives issues de myéloïdes
|
EP3137119B1
(fr)
|
2014-04-28 |
2020-07-01 |
Phio Pharmaceuticals Corp. |
Procédés de traitement du cancer au moyen d'un acide nucléique ciblant mdm2
|
JP2017514908A
(ja)
|
2014-05-01 |
2017-06-08 |
アールエックスアイ ファーマシューティカルズ コーポレーション |
核酸分子を利用する目の前部における障害の処置のための方法
|
WO2016028790A1
(fr)
|
2014-08-18 |
2016-02-25 |
Ampio Pharmaceuticals, Inc. |
Traitement de pathologies articulaires
|
EP3188799B1
(fr)
|
2014-09-05 |
2022-07-06 |
Phio Pharmaceuticals Corp. |
Méthodes de traitement de troubles cutanés et du vieillissement à l'aide d'acides nucléiques ciblant tyr ou mmp1
|
EP3201338B1
(fr)
|
2014-10-02 |
2021-11-03 |
Arbutus Biopharma Corporation |
Compositions et méthodes d'extinction de l'expression du gène du virus de l'hépatite b
|
US20180245074A1
(en)
|
2015-06-04 |
2018-08-30 |
Protiva Biotherapeutics, Inc. |
Treating hepatitis b virus infection using crispr
|
EP3310375A4
(fr)
|
2015-06-22 |
2019-02-20 |
Ampio Pharmaceuticals, Inc. |
Utilisation de fractions d'albumine de sérum humain de bas poids moléculaire pour traiter les maladies
|
CA2991598A1
(fr)
|
2015-07-06 |
2017-01-12 |
Rxi Pharmaceuticals Corporation |
Molecules d'acide nucleique ciblant la superoxyde dismutase 1 (sod1)
|
WO2017007825A1
(fr)
|
2015-07-06 |
2017-01-12 |
Rxi Pharmaceuticals Corporation |
Procédés pour le traitement de troubles neurologiques à l'aide d'une petite molécule synergique et approche thérapeutique utilisant des acides nucléiques
|
US20180208932A1
(en)
|
2015-07-29 |
2018-07-26 |
Arbutus Biopharma Corporation |
Compositions and methods for silencing hepatitis b virus gene expression
|
JP2018531037A
(ja)
|
2015-10-19 |
2018-10-25 |
アールエックスアイ ファーマシューティカルズ コーポレーション |
長い非コードrnaを標的とする減少したサイズの自己送達型核酸化合物
|
US20200123499A1
(en)
|
2015-12-02 |
2020-04-23 |
Massachusetts Institute Of Technology |
Method for efficient generation of neurons from non-neuronal cells
|
CA3066361A1
(fr)
|
2017-06-07 |
2018-12-13 |
Shifamed Holdings, Llc |
Dispositifs de deplacement de fluide intravasculaire, systemes et procedes d'utilisation
|
US11511103B2
(en)
|
2017-11-13 |
2022-11-29 |
Shifamed Holdings, Llc |
Intravascular fluid movement devices, systems, and methods of use
|
EP3713603A1
(fr)
|
2017-11-23 |
2020-09-30 |
Institut National de la Sante et de la Recherche Medicale (INSERM) |
Nouveau procédé de traitement d'une infection par le virus de la dengue
|
EP3746149A4
(fr)
|
2018-02-01 |
2021-10-27 |
Shifamed Holdings, LLC |
Pompes à sang intravasculaires et méthodes d'utilisation et procédés de fabrication
|
EP3996797A4
(fr)
|
2019-07-12 |
2023-08-02 |
Shifamed Holdings, LLC |
Pompes à sang intravasculaires et méthode d'utilisation et procédé de fabrication
|
US11654275B2
(en)
|
2019-07-22 |
2023-05-23 |
Shifamed Holdings, Llc |
Intravascular blood pumps with struts and methods of use and manufacture
|
WO2021062265A1
(fr)
|
2019-09-25 |
2021-04-01 |
Shifamed Holdings, Llc |
Dispositifs et systèmes de pompes à sang intravasculaires et leurs procédés d'utilisation et de commande
|
CN115135765A
(zh)
|
2019-11-08 |
2022-09-30 |
菲奥医药公司 |
用于免疫治疗的靶向含布罗莫结构域之蛋白4(brd4)的经化学修饰的寡核苷酸
|
US20230089478A1
(en)
|
2019-12-31 |
2023-03-23 |
Phio Pharmaceuticals Corp. |
Chemically modified oligonucleotides with improved systemic delivery
|
US20230190871A1
(en)
|
2020-05-20 |
2023-06-22 |
Sana Biotechnology, Inc. |
Methods and compositions for treatment of viral infections
|
JP2023540705A
(ja)
|
2020-08-28 |
2023-09-26 |
サナ バイオテクノロジー,インコーポレイテッド |
修飾された抗ウイルス結合剤
|
WO2023015264A1
(fr)
|
2021-08-04 |
2023-02-09 |
Phio Pharmaceuticals Corp. |
Immunothérapie anticancéreuse utilisant des cellules tueuses naturelles traitées avec des oligonucléotides chimiquement modifiés
|
JP2024529025A
(ja)
|
2021-08-04 |
2024-08-01 |
フィオ ファーマシューティカルズ コーポレーション |
化学修飾されたオリゴヌクレオチド
|